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BACKGROUND: In patients with heart failure and preserved ejection fraction, 
little is known about the characteristics of, and outcomes in, those with and 
without diabetes mellitus.
METHODS: We examined clinical and echocardiographic characteristics and 
outcomes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved 
Ejection Fraction) according to history of diabetes mellitus. Cox regression 
models were used to estimate hazard ratios for cardiovascular outcomes 
adjusted for known predictors, including age, sex, natriuretic peptides, and 
comorbidity. Echocardiographic data were available in 745 patients and were 
additionally adjusted for in supplementary analyses.
RESULTS: Overall, 1134 of 4128 patients (27%) had diabetes mellitus. 
Compared with those without diabetes mellitus, they were more likely to have a 
history of myocardial infarction (28% versus 22%), higher body mass index (31 
versus 29 kg/m2), worse Minnesota Living With Heart Failure score (48 versus 
40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 
versus 320 pg/mL; all P<0.01), more signs of congestion, but no significant 
difference in left ventricular ejection fraction. Patients with diabetes mellitus had 
a greater left ventricular mass and left atrial area than patients without diabetes 
mellitus. Doppler E-wave velocity (86 versus 76 cm/s; P<0.0001) and the E/e’ 
ratio (11.7 versus 10.4; P=0.010) were higher in patients with diabetes mellitus. 
Over a median follow-up of 4.1 years, cardiovascular death or heart failure 
hospitalization occurred in 34% of patients with diabetes mellitus versus 22% 
of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% confidence 
interval, 1.49–2.05), and 28% versus 19% of patients with and without diabetes 
mellitus died (adjusted hazard ratio, 1.59; confidence interval, 1.33–1.91).
CONCLUSIONS: In heart failure with preserved ejection fraction, patients with 
diabetes mellitus have more signs of congestion, worse quality of life, higher 
N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosis. They 
also display greater structural and functional echocardiographic abnormalities. 
Further investigation is needed to determine the mediators of the adverse 
impact of diabetes mellitus on outcomes in heart failure with preserved 
ejection fraction and whether they are modifiable.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique 
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Diabetes mellitus is common in patients with heart failure (HF) and preserved ejection fraction (HFpEF). It has been suggested that diabetes mellitus plays 
a central pathophysiological role in the development of 
HFpEF, although the exact mechanisms are debated and 
there are few comparative data on cardiac structure and 
function in patients with HFpEF with and without diabe-
tes mellitus.1–4 In addition, although it is well known that 
diabetes mellitus is associated with worse outcomes in 
patients with HF and reduced ejection fraction, less is 
known about the clinical and echocardiographic charac-
teristics of and outcomes in patients with HFpEF with 
diabetes mellitus compared with those without diabetes 
mellitus.1–3 The importance of better understanding the 
relationship between diabetes mellitus and HF has been 
underscored by recent trials in patients with type 2 di-
abetes mellitus that have suggested that some drugs 
(thiazolidinediones and possibly certain dipeptidyl pep-
tidase-4 inhibitors) may increase the risk of HF4–6 and 
others (the sodium glucose cotransporter 2 inhibitor em-
pagliflozin) may decrease the risk.7 Three glucagon-like 
peptide-1 agonist trials have shown no clear-cut effect 
on HF.8–10 The aforementioned trials largely reported inci-
dent HF, and there are few data on the effect of antidia-
betes drugs in patients with established HF. One notable 
exception is a recent trial demonstrating no benefit of 
liraglutide in patients with HF and reduced ejection frac-
tion recently hospitalized with decompensation.11
Although the type of HF affected by these treatments 
was not characterized in any of the trials mentioned, it 
is likely that many or even most cases were HFpEF.12 
With this study, we aimed to give clinicians a better un-
derstanding of the consequences of diabetes mellitus 
in patients with HFpEF and to give insight into potential 
pathophysiological mechanisms and therapeutic targets 
for future research.
In the present study, we examined the risk of adverse 
cardiovascular outcomes according to diabetes status 
adjusted for known risk factors in the I-Preserve trial (Ir-
besartan in Heart Failure With Preserved Ejection Frac-
tion). In a subgroup of patients, a full echocardiographic 
examination was performed13 that allowed a detailed 
comparison of cardiac structure and function in patients 
with HFpEF with and without diabetes mellitus.
METHODS
I-Preserve was a randomized trial that examined the effects of 
the angiotensin II receptor antagonist irbesartan on morbidity 
and mortality in patients with HFpEF.14 The rationale, design, 
and findings from I-Preserve have previously been reported.14–16 
Briefly, patients enrolled in the trial were ≥60 years of age and 
had HF symptoms and a left ventricular (LV) ejection fraction 
(LVEF) ≥45%. In addition, patients who had been hospitalized 
for HF during the previous 6 months were required to have 
current New York Heart Association class II, III, or IV symptoms 
and echocardiographic, electrocardiographic, or chest x-ray 
findings supporting a diagnosis of HF or underlying cardiac 
disease. If they had not been recently hospitalized for HF, they 
were required to have ongoing class III or IV symptoms with 
the corroborative evidence described above. The corrobora-
tive evidence required was at least one of pulmonary conges-
tion on a chest x-ray, LV hypertrophy or an enlarged left atrium 
on an echocardiogram, or LV hypertrophy or left bundle-branch 
block on an ECG. Details of these criteria have been described 
previously.14
Angiotensin-converting enzyme inhibitor therapy was lim-
ited to those patients with a specific indication other than 
hypertension (eg, diabetes mellitus with complications and sig-
nificant coronary or peripheral artery disease). In addition, only 
one third of randomized patients at each site were permitted 
to be treated with an angiotensin-converting enzyme inhibitor. 
Treatment with an angiotensin II receptor blocker was prohib-
ited, although a patient could be enrolled if angiotensin II recep-
tor blocker treatment was discontinued at least 14 days earlier. 
Exclusion criteria included a systolic blood pressure <100 or 
>160 mm Hg or a diastolic blood pressure >95 mm Hg despite 
antihypertensive therapy, a creatinine level >2.5 mg/dL (221 
μmol/L), or a potassium concentration >5.2 mmol/L. The 
ethics committee of each of the 293 participating sites in 25 
countries approved the trial, and all patients provided informed 
Clinical Perspective
What Is New?
• Among individuals with heart failure and preserved 
ejection fraction, those with diabetes mellitus have 
more evidence of congestion and higher N-terminal 
pro-B-type natriuretic peptide concentrations com-
pared with patients with heart failure and preserved 
ejection fraction without diabetes mellitus.
• The former patients also reported worse health-
related quality of life and had a higher risk of cardio-
vascular mortality and hospitalization.
• They had more structural and functional echocar-
diographic abnormalities, including evidence of 
elevated left ventricular filling pressure, which may, 
at least in part, mediate the adverse consequences 
of diabetes mellitus in patients with heart failure and 
preserved ejection fraction.
What Are the Clinical Implications?
• The study underlines the need for further investiga-
tion of which treatment approaches to both heart 
failure and diabetes mellitus might improve out-
comes in patients with both conditions.
• The finding of more signs of congestion, higher 
N-terminal pro-B-type natriuretic peptide levels and 
echocardiographic evidence of higher filling pres-
sures in patients with compared with those without 
diabetes mellitus raises the possibility that more 
intensive diuretic therapy might be therapeutically 
helpful, although this hypothesis needs to be tested 
prospectively in a clinical trial.
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consent. Detailed echocardiographic measurements were 
made in a subset of 745 patients at baseline, as described 
previously.8 Cardiovascular outcomes and all-cause mortality 
did not differ between patients randomly assigned to irbesar-
tan or placebo.15
Outcomes
For this report, the primary outcome examined was the com-
posite of cardiovascular death or HF hospitalization, as well 
as each of the components of this composite separately. 
This composite was slightly different from the original primary 
outcome of I-Preserve, which was all-cause mortality or pro-
tocol-specified cardiovascular hospitalization (HF, myocardial 
infarction, stroke, unstable angina, ventricular or atrial dys-
rhythmia), but in keeping with the primary composite outcome 
of most recent HF trials. We also report all-cause mortality.
All deaths and hospitalizations were adjudicated by an inde-
pendent end-point committee.
Statistical Analyses
Baseline characteristics are presented as means with stan-
dard deviations for continuous variables and frequencies and 
percentages for categorical variables. Differences in baseline 
characteristics according to diabetes mellitus were assessed 
with a χ2 test for categorical covariates and 2-sided t tests 
and Kruskal-Wallis test as appropriate. Tests for interactions 
between diabetes mellitus and age, sex, and ischemic origin 
were performed, but none were significant. Incidence rates of 
the outcomes of interest are presented per 100 person-years, 
and the risks of HF hospitalization, cardiovascular death, and 
the composite outcome were estimated as hazard ratios in 
Cox regression models with those with no history of diabe-
tes mellitus used as reference. The adjusted model included 
variables previously validated for the I-Preserve study16: age, 
sex, quality of life, hospitalization for HF in the past 6 months, 
LVEF, heart rate, ischemic origin, estimated glomerular filtra-
tion rate, N-terminal pro-B-type natriuretic peptide (NT-proBNP; 
log transformed), neutrophils (log transformed), chronic 
obstructive pulmonary disease/asthma, and previous myocar-
dial infarction. The outcomes of interest were also assessed 
by cumulative incidence plots with the Nelson-Aalen method. 
We conducted competing-risk analyses for all nonfatal events 
(and for cardiovascular death, the competing risk of all-cause 
death) using the Fine and Gray approach for the subdistribu-
tion of a competing risk.17 As a supplementary analysis, we 
stratified patients with diabetes mellitus according to insulin 
use and nonuse.
In patients with echocardiographic measurements available, 
we further adjusted for LV systolic and diastolic properties and 
measurements of LV structure. These results are presented 
separately as a subgroup analysis. To explore the potential for 
overfitting of the model with echocardiographic data that were 
available in only a subset of patients, we conducted sensitivity 
analyses. In the first, we removed end-systolic left atrial area 
and LV mass from the model, and in the second, we calculated 
a single continuous risk score variable from the previously 
described multivariable risk score for I-Preserve and added 
this to a model with the echocardiographic measurements. 
We did not adjust for randomization arm because irbesartan 
had no effect on any outcome in I-Preserve and no interac-
tion with diabetes mellitus was found. All P values are 2 sided, 
and a value of P<0.05 was considered significant. All analyses 
were performed separately with Stata version 14 (StataCorp, 
College Station, TX).
RESULTS
Baseline Characteristics
Overall, 1134 of 4128 patients (27%) enrolled in I-Pre-
serve had a diagnosis of diabetes mellitus at baseline. 
The characteristics of patients with and without diabetes 
mellitus at baseline are shown in Table 1. Patients with 
diabetes mellitus were slightly younger and had higher 
heart rate and body mass index but not statistically dif-
ferent blood pressure and renal function. Furthermore, 
patients with diabetes mellitus had higher NT-proBNP, 
despite no difference in LVEF and prevalence of atrial 
fibrillation. They were more likely to have an ischemic 
origin, were about twice as likely to have undergone 
percutaneous coronary intervention or coronary artery 
bypass grafting (20% versus 11%), and were more 
likely to have had a stroke. Although patients with and 
without diabetes mellitus did not differ in distribution of 
New York Heart Association class, those with diabetes 
mellitus had a significantly worse quality of life as mea-
sured by the Minnesota Living With Heart Failure score. 
Background use of medications was comparable except 
for angiotensin-converting enzyme inhibitor and lipid-
lowering drugs, both of which were more common in pa-
tients with diabetes mellitus. Signs and symptoms of HF 
and electrocardiographic findings of LV hypertrophy, left 
bundle-branch block, and atrial fibrillation/flutter did not 
differ significantly between those with and those without 
diabetes mellitus at baseline.
Echocardiographic Measurements
Of the 745 patients in the echocardiographic sub-
study, 187 (25%) had diabetes mellitus (Table 2). The 
echocardiographic data were incomplete, especially 
for certain measurements of diastolic function. We 
had a measurement of LVEF in all 745 patients, left 
atrial area in 696 patients, and end-systolic LV volume 
in 581 patients. The E/A ratio was available in 647 
patients, but the E/e ratio was available in only 515 
patients. The baseline characteristics of this subset of 
patients are presented in Table I in the online-only Data 
Supplement. The differences between patients with 
and without diabetes mellitus in this subset reflected 
those in the overall trial.
In terms of LV structure, patients with diabetes melli-
tus had a larger end-systolic dimension (3.3±0.7 versus 
3.2±0.7 cm; P=0.02), larger end-diastolic dimension 
(4.9±0.6 versus 4.8±0.6 cm; P=0.044), and greater LV 
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Table 1. Baseline Characteristics Stratified by Presence of Diabetes Mellitus in I-Preserve
 
All Patients
(N=4128)
No Diabetes Mellitus
(n=2994)
Diabetes Mellitus
(n=1134) P Value
Age, mean, y, n (%) 72±7 72±7 71±7 0.0006
  ≥65 y 3388 (82) 2480 (83) 908 (80) 0.04
  ≥75 y 1413 (34) 1036 (35) 377 (33) 0.41
Female sex, n (%) 2491 (60) 1802 (60) 689 (61) 0.74
Race, n (%)    <0.0001
  White 3859 (94) 2829 (95) 1030 (91)  
  Black 82 (2) 47 (2) 35 (3)  
  Other 187 (4) 118 (4) 69 (6)  
EF, % 59±9 59±9 60±9 0.45
Body mass index, kg/m2, n (%) 30±5 29±5 31±6 <0.0001
  Underweight (<18.5 kg/m2) 20 (1) 20 (1) 0 (0) <0.0001
  Normal (18.5–24.9 kg/m2) 624 (15) 514 (17) 110 (10)  
  Overweight (25–29.9 kg/m2) 1744 (42) 1311 (44) 433 (38)  
  Obese (≥30 kg/m2) 1740 (42) 1149 (38) 591 (52)  
Symptoms, n (%)
  NYHA class    0.07
   I 1 (0) 0 (0) 1 (0)  
   II 870 (21) 653 (22) 217 (19)  
   III 3144 (76) 2264 (76) 880 (78)  
   IV 112 (3) 76 (3) 36 (3)  
Minnesota Living With Heart Failure score 42 (28–58) 40 (27–55) 48 (30–55) <0.0001
Examination findings
  Rales, n (%) 1158 (28) 811 (27) 347 (31) 0.0250
  CXR congestion, n (%) 1590 (39) 1086 (36) 505 (44) <0.0001
  Jugular venous distention, n (%) 346 (8) 229 (8) 117 (10) 0.0060
  Edema, n (%) 2255 (55) 1609 (54) 646 (57) 0.0631
  Third heart sound, n (%) 338 (8) 227 (8) 111 (10) 0.0217
  Heart rate, bpm 71±10 71±10 72±10 <0.0001
  Systolic blood pressure, mm Hg 136±15 136±15 137±15 0.64
ECG findings
  Left bundle-branch block, n (%) 336 (8) 247 (8) 89 (8) 0.67
  LV hypertrophy, n (%) 1260 (31) 934 (31) 326 (29) 0.13
  QRS duration (no pacemaker), ms 0.10±0.05 0.10±0.06 0.10±0.06 0.1784
  Atrial fibrillation/flutter, n (%) 697 (17) 497 (17) 200 (18) 0.47
Laboratory measurements
  NT-proBNP, median (quartiles 1–3), pg/mL 339 (134–964) 320 (128–945) 403 (154–1023) 0.0074
  eGFR, ml/min/1.73m2 70 (55–85) 70 (56–84) 69 (53–86) 0.3362
  CKD (eGFR <60 ml/min/1.73m2), n (%) 1363 (33) 962 (32) 401 (35) 0.0488
  Hemoglobin, g/dL 14.0±1.5 14.1±1.4 13.8±1.6 <0.0001
  Anemia (<11 women/<13 men), n (%) 514 (13) 304 (11) 210 (19) <0.0001
  Neutrophils (quartiles 1–3), cells/µL 4.3 (3.4–5.3) 4.2 (3.3–5.2) 4.6 (3.7–5.6) <0.0001
(Continued )
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mass (173±48 versus 161±48 g; P=0.004), but the 
relative wall thickness was similar (0.40±0.08 versus 
0.40±0.08; P=0.40). No significant differences were 
seen for LV systolic properties, although fractional short-
ening tended to be lower in diabetic patients (33±10% 
versus 35±10%; P=0.09).
Details of LV diastolic function are shown in Table 2. 
Early diastolic mitral inflow velocity (E) was significantly 
higher in patients with diabetes mellitus (86±32 versus 
76±27 cm/s; P≤0.0001), as was the E/e’ ratio (11.7 
versus 10.4; P=0.001), where e’ is the average of later-
al and septal annular velocities by tissue Doppler. Twen-
ty-seven percent of patients with diabetes mellitus and 
14% of those without had an E/e’avg >14 (P=0.001), sug-
gesting significantly more diastolic dysfunction among 
patients with diabetes mellitus.18 E/A was also higher 
among patients with diabetes mellitus (1.18±0.97 ver-
sus 1.00±0.65; P=0.01). Left atrial area was greater 
(24±6 versus 23±6 cm2; P=0.003), as was the pro-
portion of individuals with an enlarged left atrium (75% 
versus 66%; P=0.02), compared with patients without 
diabetes mellitus.
Medical history, n (%)
  HF hospitalization within 6 mo 1816 (44) 1294 (43) 522 (46) 0.1042
  Ischemic origin 1036 (25) 710 (24) 326 (29) 0.0009
  Hypertensive origin 2622 (64) 1960 (66) 662 (58) <0.0001
  Myocardial infarction 969 (23) 655 (22) 314 (28) <0.0001
  Stable angina pectoris 1652 (40) 1217 (41) 435 (38) 0.1804
  Unstable angina pectoris 315 (8) 197 (7) 118 (10) <0.0001
  Hypertension 3650 (88) 2625 (88) 1025 (90) 0.0150
  Atrial fibrillation 1209 (29) 868 (29) 341 (30) 0.50
  Stroke 399 (10) 263 (9) 136 (12) 0.002
  COPD/asthma 391 (10) 262 (9) 129 (11) 0.0101
  PCI or CABG 548 (13) 327 (11) 221 (20) <0.0001
  ICD 12 (0) 6 (0) 6 (1) 0.08
  Pacemaker 252 (6) 168 (6) 84 (7) 0.0314
Medication, n (%)
  Any diuretic 3418 (83) 2462 (82) 956 (84) 0.11
  Loop diuretic 2150 (52) 1480 (50) 670 (59) <0.0001
  ACE inhibitor 1033 (25) 615 (21) 418 (37) <0.0001
  β-Blocker 2427 (59) 1774 (59) 653 (58) 0.33
  Calcium channel blocker 1637 (40) 1179 (39) 458 (40) 0.55
  Long-acting nitrates 1108 (27) 775 (26) 333 (29) 0.02
  Mineralocorticoid antagonists 633 (15) 451 (15) 182 (16) 0.43
  Digoxin 561 (14) 390 (13) 171 (15) 0.09
  Lipid-lowering drugs 1047 (25) 667 (22) 380 (34) <0.0001
  Antiplatelets, any 2416 (59) 1723 (58) 693 (61) 0.04
  Metformin 284 (7) 0 (0) 284 (25) <0.0001
  Other oral antidiabetic agents 544 (13) 2 (0) 542 (48) <0.0001
  Insulin 339 (8) 0 (0) 339 (30) <0.0001
ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary 
disease; CXR, chest x-ray; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; 
I-Preserve, Irbesartan in Heart Failure With Preserved Ejection Fraction; LV, left ventricular; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, 
New York Heart Association; and PCI, percutaneous coronary intervention. NT-proBNP was available for 3479 patients (84%) and Minnesota Living With 
Heart Failure for 3181 patients (77%).
Table 1. Continued
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Clinical Outcomes
The unadjusted rates of the composite end point of car-
diovascular death or HF hospitalization and all-cause 
mortality were higher in patients with diabetes mellitus 
(Table 3 and Figures 1 and 2).
Over a median of 4.1 years of follow-up, the compos-
ite end point occurred in 391 patients (34%) with diabe-
tes mellitus compared with 662 patients without (22%), 
with event rates of 10.2 and 5.7 per 100 person-years, 
respectively. After adjustments for known predictive 
variables (see Methods), the hazard ratio for patients 
with diabetes mellitus compared with those without was 
1.75 (95% confidence interval, 1.49–2.05). Competing-
risk analyses gave comparable results (Table II in the 
Table 2. Echocardiographic Data According to Diabetes Status
 No Diabetes Mellitus (n=558) Diabetes Mellitus (n=187) P Value Normal Range
Age, y 72±7 72±7 0.97  
Female, n (%) 351 (63) 108 (58) 0.21  
LV structure
  End-diastolic dimension, cm 4.8±0.6 4.9±0.6 0.044 4.0–6.0
  End-diastolic volume, mL 93±38 98±38 0.15 80–180
  End-systolic dimension, cm 3.2±0.7 3.3±0.7 0.02 2.0–4.0
  End-systolic volume, mL 34±18 37±19 0.074 25–50
  Septum wall thickness, cm 0.97±0.16 1.00±0.16 0.04 0.8–0.9
  Mass, g 161±48 173±48 0.004 80–140
  Relative wall thickness 0.40±0.08 0.40±0.08 0.40 0.36–0.40
  LV hypertrophy, n (%) 384 (69) 147 (79) 0.01  
LV systolic properties
  Fractional shortening, % 35±10 33±10 0.09 30–45
  EF, % 64±9 63±10 0.13 55–75
  Stroke volume, mL 59±24 61±25 0.405 50–70
  S´ lateral 8.2±2.3 8.2±2.3 0.72 6–14
LV diastolic properties
  Diastolic dysfunction   0.30  
   Grade I, n (%) 194(38) 54 (32)   
   Grade II, n (%) 28 (6) 14 (8)   
   Grade III, n (%) 282 (55) 95 (57)   
   Grade IV, n (%) 7 (1) 4 (2)   
   E, cm/s 76±27 86±32 <0.0001 40–90
   E/e l´ateral ratio 9.5±3.9 10.5±5.9 0.03 4.5–11.5
   E/e´
average
 ratio 10.4±3.9 11.7±6.4 0.001 <10
   A, cm/s 82±25 84±28 0.41 40–100
   E/A 1.00±0.65 1.18±0.97 0.01 0.6–1.4
   E´ lateral annulus, cm/s 9.1±3.5 9.4±3.2 0.35 7.0–11.5
   E´ septal annulus, cm/s 7.4±2.3 7.1±2.5 0.26 5.0–11.0
   IVRT, ms 97±22 93±21 0.053 4.5–11.5
   E deceleration time 217±78 211±75 0.38 60–130
  Left atrial area, cm2 23±6 24±6 0.003 10–20
  Enlarged left atria, n (%) 366 (66) 140 (75) 0.02  
  Left atrial volume index 44.1±17.8 46.8±19.1 0.15 16–34
  RV systolic pressure, mm Hg 26±13 28±14 0.28 15–25
EF indicates ejection fraction; IVRT, isovolumic relaxation time; and RV, right ventricular. LV hypertrophy is LV mass >140 g.
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online-only Data Supplement). The pattern of higher risk 
associated with diabetes mellitus (hazard ratio, 1.79; 
confidence interval, 1.28–2.51 for the composite end 
point) was also seen in the echocardiography subgroup, 
although this risk was no longer statistically significant 
(hazard ratio, 1.45; confidence interval, 0.82–2.59) after 
further adjustment for echocardiographic variables (see 
Methods and Table 4), possibly because of the smaller 
sample size. The sensitivity analyses of the models that 
included echocardiographic data showed similar results.
Diabetes mellitus was associated with higher rates of 
all-cause death, cardiovascular death, and noncardiovas-
cular death. The elevated risks of these outcomes per-
sisted after adjustments for known prognostic variables 
(Table 3). Mode of death according to the presence 
or absence of diabetes mellitus is depicted in Table 5. 
Pump failure and sudden cardiac death were more fre-
quent in patients with diabetes mellitus, whereas rates of 
fatal myocardial infarction and stroke were similar.
HF hospitalization occurred in 253 patients (22%) with 
diabetes mellitus compared with 408 patients (14%) with-
out diabetes mellitus, yielding event rates of 6.6 and 3.5 
per 100 person-years, giving a diabetes mellitus/no dia-
betes mellitus–adjusted hazard ratio of 1.77 (95% confi-
dence interval, 1.45–2.16). When repeat HF hospitaliza-
tions were included, 708 admissions occurred in those 
with diabetes mellitus and 468 in individuals without dia-
betes mellitus, resulting in event rates of 9.3 and 5.7 per 
100 person-years, respectively. The number and rates of 
admission to hospital for any reason and for cardiovascu-
lar and noncardiovascular reasons separately were also 
higher in individuals with diabetes mellitus compared with 
those without (Table 3). Results stratified by use/nonuse 
of insulin treatment in patients with diabetes mellitus are 
Table 3. Outcomes According to Diabetes Mellitus in I-Preserve
 Patients, n Events, n (%)
Event Rate, n/
100 Patient-y
Unadjusted HR 
(95% CI)
Adjusted* HR (95% 
CI)
Cardiovascular death or HF hospitalization
  No history of diabetes mellitus 2994 662 (22) 5.7 (5.3–6.2) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 391 (34) 10.2 (9.2–11.3) 1.76 (1.55–1.99) 1.75 (1.49–2.05)
Cardiovascular death
  No history of diabetes mellitus 2994 393 (13) 3.2 (2.9–3.5) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 220 (19) 5.0 (4.4–5.7) 1.61 (1.36–1.89) 1.59 (1.28–1.96)
HF hospitalization
  No history of diabetes mellitus 2994 408 (14) 3.5 (3.2–3.9) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 253 (22) 6.6 (5.8–7.5) 1.82 (1.55–2.13) 1.77 (1.45–2.16)
All-cause mortality
  No history of diabetes mellitus 2994 567 (19) 4.6 (4.2–5.0) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 314 (28) 7.2 (6.4–8.0) 1.59 (1.39–1.83) 1.59 (1.33–1.91)
Noncardiovascular death
  No history of diabetes mellitus 2994 174 (6) 1.4 (1.2–1.6) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 94 (8) 2.1 (1.8–2.6) 1.57 (1.22–2.02) 1.60 (1.14–2.25)
All-cause hospitalization
  No history of diabetes mellitus 2994 1520 (51) 17.3 (16.5–18.2) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 708 (62) 26.2 (24.3–28.2) 1.45 (1.33–1.59) 1.51 (1.34–1.70)
Cardiovascular hospitalization
  No history of diabetes mellitus 2994 815 (27) 7.8 (7.3–8.4) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 374 (33) 10.7 (9.7–11.8) 1.33 (1.17–1.50) 1.34 (1.14–1.57)
Noncardiovascular hospitalization
  No history of diabetes mellitus 2994 699 (23) 6.5 (6.0–7.0) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 1134 331 (29%) 9.2 (8.3–10.2) 1.37 (1.21–1.57) 1.41 (1.19–1.68)
CI indicates confidence interval; HF, heart failure; HR, hazard ratio; and I-Preserve, Irbesartan in Heart Failure With Preserved Ejection Fraction. 
*Adjusted for age, sex, quality of life, log N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, heart rate, neutrophils, ejection 
fraction, hospitalization for HF in past 6 months, ischemic origin, history of myocardial infarction, and history of chronic obstructive pulmonary disease/
asthma.
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shown in Table III in the online-only Data Supplement, 
which displays a step-wise worsening, with the highest 
risk in patients with diabetes mellitus who were treated 
with insulin.
Adverse Events
Serious adverse events and drug discontinuation be-
cause of adverse events (excluding death) are listed in 
Table IV in the online-only Data Supplement. Overall, seri-
ous adverse events were rare, but increased potassium, 
chronic kidney disease, and cough were more prevalent 
in patients with diabetes mellitus (all P<0.05). Drug dis-
continuation as a result of adverse events other than 
death was also more likely in patients with diabetes mel-
litus (23% versus 17%; P=0.0008).
DISCUSSION
There is only 1 other report from a large clinical trial 
comparing the characteristics of and outcomes in pa-
tients with HFpEF with and without diabetes mellitus. 
However, in that publication from the CHARM program 
(Candesartan in Heart Failure: Assessment of Reduction 
in Mortality and Morbidity), an LVEF cut point of 40% was 
used, natriuretic peptides were not measured, echocar-
diography data were unavailable, and health-related qual-
ity of life was not reported.5 In the present study, we 
fill these gaps and describe a number of novel findings. 
We found that patients with diabetes mellitus, despite no 
statistically significant differences in age, sex distribu-
tion, and average LVEF, had a different pattern of co-
morbidity/pathogenesis (more coronary heart disease/
less hypertension), a higher median NT-proBNP (despite 
a greater prevalence of obesity), more evidence of con-
gestion, worse quality of life, and more cardiac remodel-
ing with higher LV mass and more evidence of diastolic 
dysfunction than patients without diabetes mellitus. In 
addition, we found that the relationship between diabe-
tes mellitus and higher risk of cardiovascular outcomes 
persisted after adjustment for NT-proBNP.
It was notable that despite a similar distribution of 
New York Heart Association class and LVEF, variables 
commonly used to characterize the severity of HF, pa-
tients with diabetes mellitus had a higher (worse) Minne-
sota Living With Heart Failure score, with values similar 
to those found in patients with HF and reduced ejection 
fraction with diabetes mellitus. The differential between 
patients with HFpEF with and without diabetes mellitus in 
I-Preserve (48 versus 40) was very similar to that seen 
in another study of the effects of phosphodiesterase-5 
inhibition in HFpEF: Patients without diabetes mellitus 
(n=123) had a mean score of 42 compared with 47 in 
patients with diabetes mellitus (n=93).19 This worse self-
reported HF-related quality of life may have a number of 
explanations, one of which may be the greater severity 
of congestion documented by edema, rales, and jugular 
venous distension in patients with diabetes mellitus (and 
supported by greater diuretic use, elevated natriuretic 
peptides, and left atrial enlargement; see below). The 
phosphodiesterase-5 inhibitor trial mentioned above 
also found more edema in patients with diabetes mel-
litus, and those patients had reduced functional capacity 
compared with patients without diabetes mellitus. That 
patients with diabetes mellitus exhibit more congestion 
may be relevant to the increased risk of HF with hypogly-
cemic drugs causing sodium and water retention (thia-
zolidinediones) and reduced risk with those acting as a 
diuretic (sodium-glucose cotransporter-2 inhibitors).12,18 
These findings might also help clinicians decide in which 
patients to target new treatments in HFpEF, depending 
on their mode of action. The substantially worse Min-
nesota Living With Heart Failure score in patients with 
HFpEF and diabetes mellitus also suggests that health-
Figure 1. Cumulative incidence plot for the composite 
end point of cardiovascular death or heart failure 
hospitalization according to history of diabetes  
mellitus.
Figure 2. Cumulative incidence plot for all-cause 
mortality according to history of diabetes mellitus.
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related quality of life may be a worthwhile end point in 
future trials in these patients.
Also notable was the considerably higher median NT-
proBNP concentration in patients with diabetes mellitus, 
especially given the greater prevalence of obesity that 
is associated with lower natriuretic peptide concentra-
tions.19 Again, there may be a number of explanations 
for this. Greater congestion, as alluded to above, may 
be one. Impaired renal function (which was slightly more 
common in patients with diabetes mellitus) may be an-
other. Atrial fibrillation was not more common in patients 
with diabetes mellitus, but those patients had more func-
tional and structural cardiac abnormalities than patients 
without diabetes mellitus.
The echocardiography substudy from I-Preserve 
provides some of the most unique data in the present 
report. Specifically, patients with diabetes mellitus had 
slightly larger LV dimensions and greater LV mass com-
pared with patients without diabetes mellitus. The latter 
finding, along with the differences we found in mitral 
inflow and tissue Doppler measurements, suggests in-
creased LV stiffness, impaired LV filling, and higher left 
atrial pressure (supported by higher NT-proBNP concen-
trations) in patients with compared with those without 
diabetes mellitus.20 The phosphodiesterase-5 inhibitor 
trial also reported echocardiographic findings that were 
largely consistent with ours, although the differences be-
tween patients with and without diabetes mellitus were 
less often significant, possibly because of the small 
sample size. One community-based cohort study also 
reported that patients with HFpEF with diabetes melli-
tus had a greater LV mass and higher E/e’ than patients 
without diabetes mellitus.20 Collectively, however, the dif-
ferences in diastolic function between patients with and 
Table 4. Outcomes According to Diabetes Mellitus in I-Preserve (Only Patients With Echocardiographic Data)
 Patients, n Events, n (%)
Event Rate, n/
100 Patient-y
Unadjusted HR  
(95% CI)
Adjusted* HR  
(95% CI)
Cardiovascular death or HF hospitalization
  No history of diabetes mellitus 558 96 (17) 4.8 (3.9–5.9) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 52 (28) 8.8 (6.7–11.5) 1.79 (1.28–2.51) 1.45 (0.82–2.59)
Cardiovascular death
  No history of diabetes mellitus 558 44 (8) 2.1 (1.5–2.8) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 28 (15) 4.1 (2.8–6.0) 1.99 (1.24–3.19) 1.84 (0.76–4.45)
HF hospitalization
  No history of diabetes mellitus 558 61 (11) 3.1 (2.4–3.9) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 36 (19) 6.1 (4.4–8.4) 1.94 (1.29–2.93) 1.55 (0.76–3.20)
All-cause mortality
  No history of diabetes mellitus 558 74 (13) 3.5 (2.8–4.4) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 43 (23) 6.3 (4.7–8.5) 1.82 (1.25–2.65) 2.12 (1.07–4.18)
Noncardiovascular death
  No history of diabetes mellitus 558 30 (5) 1.4 (1.0–2.0) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 15 (8) 2.2 (1.3–3.7) 1.57 (0.85–2.93) 3.63 (1.08–12.20)
All-cause hospitalization
  No history of diabetes mellitus 558 273 (49) 17.8 (15.8–20.0) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 115 (61) 28.2 (23.5–33.8) 1.53 (1.23–1.90) 1.50 (1.04–2.18)
Cardiovascular hospitalization
  No history of diabetes mellitus 558 133 (24) 7.2 (6.1–8.6) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 54 (29) 10.0 (7.7–13.1) 1.34 (0.98–1.84) 1.11 (0.63–1.96)
Noncardiovascular hospitalization
  No history of diabetes mellitus 558 140 (25) 7.7 (6.5–9.1) 1.00 (Referent) 1.00 (Referent)
  Diabetes mellitus 187 61(33) 11.1 (8.7–14.3) 1.42 (1.05–1.92) 1.64 (1.01–2.67)
CI indicates confidence interval; HF, heart failure; HR, hazard ratio; and I-Preserve, Irbesartan in Heart Failure With Preserved Ejection Fraction. 
*Adjusted for age, sex, quality of life, log N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, heart rate, neutrophils, ejection 
fraction, hospitalization for HF in past 6 months, ischemic origin, history of myocardial infarction, history chronic obstructive pulmonary disease/asthma, 
left ventricular end-systolic volume, left ventricular mass, ejection fraction, E/E’ ratio, and left atrial area.
Diabetes Mellitus in HFpEF
ORIGINAL RESEARCH 
ARTICLE
Circulation. 2017;135:724–735. DOI: 10.1161/CIRCULATIONAHA.116.024593 February 21, 2017 733
without diabetes mellitus in our study and the other stud-
ies mentioned were relatively modest despite the preva-
lent view that diastolic dysfunction is a pathognomonic 
feature of diabetes-related cardiac disease.
Last, we found that patients with HFpEF and diabe-
tes mellitus had worse outcomes than patients with HF-
pEF without diabetes mellitus. This was also true in the 
CHARM program and the DIG trial (Digitalis Investigators 
Group) ancillary study in patients with an LVEF >45% 
(285 of the 987 patients had diabetes mellitus).7 In the 
Olmsted County epidemiological study, diabetes mellitus 
was independently predictive of death (and cardiovas-
cular death) in a community HF cohort, regardless of 
ejection fraction.21 However, unlike in these earlier trials, 
we were able to adjust outcomes for NT-proBNP levels. 
Despite adjustment for NT-proBNP and other prognos-
tic variables, patients with diabetes mellitus were 1.5 
to 2.0 times as likely to have an adverse clinical out-
come. In contrast, we found that, after additional adjust-
ment for LV end-systolic volume, LV mass, E/e’, and left 
atrial area in the echocardiographic subgroup, the risk 
associated with diabetes mellitus was no longer statisti-
cally significant (Table 4), possibly because of either the 
smaller sample size of the echocardiographic subgroup 
or because adverse LV remodeling is an important me-
diator of the risk associated with diabetes mellitus. The 
excess risk associated with diabetes mellitus was seen 
for death and for HF hospitalization and was apparent for 
both cardiovascular and noncardiovascular death; that 
is, no specific type of event seemed to be particularly 
increased in patients with diabetes mellitus. Adjustment 
for echocardiographic findings did not attenuate the risk 
of noncardiovascular outcomes.
Our study has a number of limitations. The analyses 
were retrospective rather than preplanned. The diagno-
sis of diabetes mellitus was investigator reported and not 
standardized. Although similar to that in DIG and CHARM 
trials, the prevalence of diabetes mellitus in I-Preserve 
was lower than in many more recent trials, presumably 
reflecting the steadily increasing prevalence of diabetes 
mellitus.2,22 The small numbers of events in those with 
echocardiographic data may have led to “overfitting” of 
the model, although sensitivity analyses found similar 
results after the removal of variables from the model. 
Last, patient selection in clinical trials limits the external 
validity of findings when extrapolated to a typical com-
munity population.
CONCLUSIONS
Among patients with HFpEF, those with diabetes mel-
litus have more signs of congestion, worse quality of 
life, higher NT-proBNP levels, greater structural and 
functional echocardiographic abnormalities, and worse 
outcomes than those without diabetes mellitus. Further 
investigation is needed to determine the mediators of 
the adverse impact of diabetes mellitus on outcomes in 
HFpEF and whether they are modifiable.
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